Justin Sherman, OD
Optometrist · Philadelphia, PANPI 1669929501
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 58.0% of the total. Among optometrist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $72.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$10K
- Alcon$1K
- Coopervision Inc.$1K
- Oyster Point Pharma, Inc.$1K
- Biotissue Holdings Inc.$928
- Johnson & Johnson Vision Care, Inc.$863
- plus $2K from 15 others
What the payments were for
- Consulting fees$2,42514%
- Speaking & faculty fees$8,82551%
- Travel & lodging$4012%
- Food & beverage$5,65933%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 51 | $10,054 |
| Alcon | 30 | $1,466 |
| Coopervision Inc. | 19 | $1,157 |
| Oyster Point Pharma, Inc. | 61 | $1,084 |
| Biotissue Holdings Inc. | 18 | $928 |
| Johnson & Johnson Vision Care, Inc. | 12 | $863 |
| Sun Pharmaceutical Industries Inc. | 21 | $770 |
| Harrow Eye, LLC | 7 | $285 |
| Glaukos Corporation | 3 | $247 |
| Rxsight Inc | 5 | $149 |
| Shire North American Group Inc | 1 | $107 |
| Dompe US, Inc. | 2 | $38 |
| Tarsus Pharmaceuticals, Inc. | 1 | $29 |
| AbbVie | 1 | $28 |
| Tearlab Corp | 1 | $23 |
| Ocular Therapeutix, Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Sight Sciences, Inc. | 1 | $17 |
| Thea Pharma Inc. | 1 | $15 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZENLENS$4,575
- REVIVE$3,914
- Clariti Contact Lens$620
- XIIDRA$589
- NOVAKONE$525
- Acuvue$500
- AIR OPTIX$500
- MIEBO$482
- CEQUA$275
- TYRVAYA$250
- CE-marked KXLA system$200
- AcrySof IQ VIVITY$144
- Clareon$131
- MiSight Contact Lens$119
- VYZULTA$115
- TRYPTYR$113
- RXSIGHT CONTACT LENS$101
- RXSIGHT INJECTOR CARTRIDGE$101
- RXSIGHT INJECTOR HANDPIECE$101
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$101
How this compares
$17,329 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TyrvayaVarenicline Tartrate | 14 | $20,392 |
| RestasisCyclosporine | 20 | $19,088 |
| MieboPerfluorohexyloctane/Pf | 22 | $16,620 |
| XiidraLifitegrast | 18 | $16,092 |
| Cyclosporine | 25 | $6,930 |
| Prednisolone Acetate | 11 | $278 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $183 |
| Latanoprost | 18 | $117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $10,054 | $32,71240 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,084 | $20,39214 claims |
| AbbVieRestasis | $28 | $19,08820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Other optometrist in Philadelphia
- Gretchen BrewerPhiladelphia$79K
- Alan KabatPhiladelphia$49K
- Melissa TregoPhiladelphia$46K
- Elizabeth TonkeryPhiladelphia$40K
- Clark ChangPhiladelphia$37K
- Tu DinhPhiladelphia$28K
- Diana ChuongPhiladelphia$10K
- David DuffyPhiladelphia$10K
- Andrew MeagherPhiladelphia$9K
- Kennard HerringPhiladelphia$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.